MarketCap
Facebook
X
TelegramQuarterly report 2026-Q3
added 05-20-2026
Haemonetics Corporation Net Income 2011-2026 | HAE
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Haemonetics Corporation
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 97.3 M | 168 M | 118 M | 115 M | 43.4 M | 79.5 M | 76.5 M | 55 M | 45.6 M | -26.3 M | -55.6 M | 16.9 M | 35.1 M | 38.8 M | 66.9 M | 80 M | 21.3 M | 59.3 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 168 M | -55.6 M | 57.5 M |
Quarterly Net Income Haemonetics Corporation
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | 2010-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 44.7 M | 38.7 M | 34 M | 44.7 M | 38.7 M | 34 M | - | 37.5 M | 33.8 M | 38.4 M | - | 31.2 M | 24.9 M | 41 M | - | 32.9 M | 33.2 M | 19.9 M | - | - | 14.9 M | -4.45 M | -4.45 M | 31.9 M | 31.9 M | 48.1 M | 10.5 M | 29.9 M | 29.9 M | 37.5 M | -8.48 M | -8.48 M | 18.3 M | 18.7 M | 11.9 M | -6.55 M | 20.1 M | 20.1 M | 20.1 M | 15.4 M | 15.4 M | 19.8 M | -10.3 M | -59.4 M | -59.4 M | 12.9 M | -267 K | 16 M | 16 M | 7.49 M | -3.65 M | 16.3 M | 16.3 M | 16.5 M | -7.87 M | 9.9 M | 9.9 M | 6.55 M | 9.79 M | 18.3 M | 18.3 M | 13.9 M | 16.9 M | 19.7 M | 21.3 M | 17.9 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 48.1 M | -59.4 M | 16.6 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Medical instruments industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
19.4 M | - | - | $ 810 M |  USA |
 |
The Cooper Companies
COO
|
375 M | $ 62.02 | 2.78 % | $ 12.3 B | USA |
 |
Luminex Corporation
LMNX
|
15.2 M | - | - | $ 1.75 B | USA |
 |
Glaukos Corporation
GKOS
|
-188 M | $ 121.69 | 7.24 % | $ 6.96 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
-17.6 M | - | -9.52 % | $ 20.6 M | USA |
 |
Intuitive Surgical
ISRG
|
2.86 B | $ 418.82 | 2.83 % | $ 149 B | USA |
 |
Alcon
ALC
|
376 M | $ 66.58 | 3.67 % | $ 40.4 B |  Schweiz |
 |
ICU Medical
ICUI
|
732 K | $ 134.93 | 3.38 % | $ 3.32 B | USA |
 |
Repro Med Systems
KRMD
|
-2.64 M | $ 4.14 | 5.61 % | $ 191 M | USA |
 |
iRhythm Technologies
IRTC
|
-44.6 M | $ 107.35 | 2.67 % | $ 3.44 B | USA |
 |
LeMaitre Vascular
LMAT
|
57.7 M | - | - | $ 2.12 B | USA |
 |
Masimo Corporation
MASI
|
-305 M | $ 178.9 | 0.07 % | $ 9.54 B | USA |
 |
Antares Pharma, Inc.
ATRS
|
56.2 M | - | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
13.7 M | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
-24.5 M | - | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
223 M | - | -0.05 % | $ 10.3 B | USA |
 |
Microbot Medical
MBOT
|
-13.1 M | - | - | $ 89.7 M |  Israel |
 |
Ekso Bionics Holdings
EKSO
|
-11.7 M | - | - | $ 28.6 M | USA |
 |
Milestone Scientific
MLSS
|
-5.72 M | $ 0.43 | 11.28 % | $ 35.3 M | USA |
 |
Varian Medical Systems, Inc.
VAR
|
292 M | - | -0.02 % | $ 16.3 B | USA |
 |
electroCore
ECOR
|
-14 M | $ 9.94 | 0.81 % | $ 84.3 K | USA |
 |
Envista Holdings Corporation
NVST
|
47 M | $ 22.87 | 2.1 % | $ 3.84 B | USA |
 |
Isoray
ISR
|
-103 M | - | 0.03 % | $ 108 M | USA |
 |
STERIS plc
STE
|
782 M | $ 212.24 | 0.98 % | $ 20.8 B | USA |
 |
STAAR Surgical Company
STAA
|
-80.4 M | $ 29.86 | 5.66 % | $ 1.48 B | USA |
 |
InfuSystem Holdings
INFU
|
6.63 M | $ 9.12 | 1.0 % | $ 188 M | USA |
 |
Teleflex Incorporated
TFX
|
-906 M | $ 132.11 | 2.76 % | $ 5.9 B | USA |
 |
Merit Medical Systems
MMSI
|
128 M | $ 63.04 | 3.94 % | $ 3.73 B | USA |
 |
Utah Medical Products
UTMD
|
2.56 M | $ 67.99 | 3.75 % | $ 220 M | USA |
 |
West Pharmaceutical Services
WST
|
494 M | $ 317.32 | 0.32 % | $ 22.9 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
-598 M | $ 9.88 | 2.49 % | $ 1.97 B | USA |
 |
Pulse Biosciences
PLSE
|
-72.8 M | $ 26.94 | 7.8 % | $ 1.82 B | USA |
 |
Retractable Technologies
RVP
|
-12.6 M | $ 0.66 | 0.41 % | $ 19.8 M | USA |
 |
Pro-Dex
PDEX
|
8.98 M | $ 67.0 | 2.81 % | $ 220 M | USA |
 |
Predictive Oncology
POAI
|
-233 M | - | - | $ 31.1 M | USA |
 |
BioLife Solutions
BLFS
|
-4.6 M | - | - | $ 1.29 B | USA |
 |
Stereotaxis
STXS
|
-21.6 M | $ 1.88 | 2.17 % | $ 171 M | USA |
 |
Baxter International
BAX
|
-957 M | $ 19.35 | 4.31 % | $ 9.93 B | USA |
 |
ResMed
RMD
|
779 M | $ 194.32 | 4.2 % | $ 28.4 B | USA |
 |
AtriCure
ATRC
|
-11.4 M | - | - | $ 1.3 B | USA |
 |
Harvard Bioscience
HBIO
|
-56.7 M | - | - | $ 288 M | USA |
 |
NeuroMetrix
NURO
|
-7.81 M | - | 5.05 % | $ 9.02 M | USA |
 |
AngioDynamics
ANGO
|
-34 M | $ 12.03 | 7.41 % | $ 491 M | USA |
 |
Becton, Dickinson and Company
BDX
|
1.68 B | $ 149.56 | 2.73 % | $ 43 B | USA |
 |
Nephros
NEPH
|
1.19 M | $ 3.59 | -1.37 % | $ 38.1 M | USA |
 |
OraSure Technologies
OSUR
|
-68.7 M | $ 4.17 | 5.57 % | $ 306 M | USA |
 |
Repligen Corporation
RGEN
|
48.9 M | $ 126.55 | 3.96 % | $ 7.12 M | USA |